Insight Molecular Diagnostics (IMDX) Retained Earnings (2020 - 2025)
Historic Retained Earnings for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$377.8 million.
- Insight Molecular Diagnostics' Retained Earnings fell 1917.12% to -$377.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$377.8 million, marking a year-over-year decrease of 1917.12%. This contributed to the annual value of -$350.5 million for FY2024, which is 2092.72% down from last year.
- Latest data reveals that Insight Molecular Diagnostics reported Retained Earnings of -$377.8 million as of Q3 2025, which was down 1917.12% from -$367.0 million recorded in Q2 2025.
- Insight Molecular Diagnostics' 5-year Retained Earnings high stood at -$127.6 million for Q1 2021, and its period low was -$377.8 million during Q3 2025.
- Moreover, its 5-year median value for Retained Earnings was -$272.5 million (2023), whereas its average is -$263.5 million.
- Per our database at Business Quant, Insight Molecular Diagnostics' Retained Earnings crashed by 5525.57% in 2022 and then tumbled by 1120.16% in 2023.
- Insight Molecular Diagnostics' Retained Earnings (Quarter) stood at -$187.8 million in 2021, then plummeted by 38.82% to -$260.7 million in 2022, then decreased by 11.2% to -$289.9 million in 2023, then dropped by 20.93% to -$350.5 million in 2024, then decreased by 7.78% to -$377.8 million in 2025.
- Its last three reported values are -$377.8 million in Q3 2025, -$367.0 million for Q2 2025, and -$357.2 million during Q1 2025.